							_	t of Commerce emark Office	Atty. Dock 0575/528		Serial No. CPA of 08/905,709					
-	INFO	OR.	M <i>A</i>	TI	ON	<b>I D</b> ]	ISC	CL(	SURE ST	ATEMENT	Applicant David St	tern and An	n-Marie S	Schmidt		
(Use several sheets					l sh	eet	s if necess:	ary)	Filing Date March 2		Group 1646					
									U.S. I	PATENT DOCUME	NTS		_			
Examiner Initial			Doc	ume	ent l	Num	ıber		Date 1/26/99	Name	Class Subclass		Filing Date if Appropriate			
EW		5	8	6	4	0	1	8	, , , , , ,	Morser et al.	530	387.1				
1		5	6	8	8	6	5	3	11/18/97	Ulrich, et al.	435	7.1				
T		5	5	8	5	3	4	4	12/17/96	Vlassara et al.	514	2				
·								<u> </u>								
	<b>.</b>								FOREIG	N PATENT DOCU	MENTS		<del></del>			
	Document Number			er	Date	Country	Class	Subclass	Tr	anslation						
				т									Yes	No		
tw	WO	9	7	3	9	1	2	5	1923/97	PCT						
	WO	9	7	3	9	1	2	1	10/23/97							
J	wo	9	7	2	6	9	1	3	7/31/97	PCT						
	wo	9	8	2	2	1	3	8		PCT		0.1				
				_		L		_					ļ			
		/	1		<u> </u>		1_		L		<u> </u>	L				
										luding Author, Title						
		Brett, J, et al., (1993) "Survey of the distribution of a														
EW		newly-characterized receptor for AGEs in tissues" Am. J. Pathol,														
		143:1699-1712.;														
		_								· · · · · · · · · · · · · · · · · · ·				7		
										J, Stern DM, Sc						
-	and strain-related variables signi:							_								
		mo	ode	1	of	£	<b>2</b> C2	al	cerebra	l ischemia. Ne	urosurg	7 1996;38	:523-5.	32.		
					_					/1006	) M-7-		oranio	a for		
	Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for												5 101			
EW	vascular diseases. <u>Science</u> 272: 689-693.															
		-		-			_									
		-														
		$\vdash$														
		$\vdash$														
EXAMIN	ER 🗸	Lici	ضا	โดว	av ·	- 11/	lo &	<u> </u>	DATE CON							
i								v	1	6/21/01			with MDED	609. Draw		
*EXAMINE	R: I:	nit ci	ial tat:	if ion	ref if	fere not	ence : ir	2 CC	onsidered, onformance	whether or not citati and not considered. I	con is in Include co	opy of this f	rom with	next		
communic	atio	n t	o a	pp1	icar	nt.					,					

attacheent # 20

Form PT(	O-1449		Department of Commerce t and Trademark Office	e	Atty. Docket No. 0575/52876		Serial No. CPA2 of 08/905,709				
. IN		ON DISCLOSURE STATEMENT		Applicant David Stern and Ann-Marie Schmidt							
	(Use s	several shee	ts if necessary)		Filing Date March 23, 2000		Group 1646				
	OTHE	R DOCUM	ENTS (Including Author	, Title	, Date, Pertinent	Pages	, Etc.)				
ļ	Hori, et al. "The Receptor for Advanced Glycation Endproducts:										
	Implications for the Development of Diabetic Vascular Disease. Funda										
Rm	Clin. Cardiol." In: The Endothelium in Clinical Practice. January 199										
1	Chapter	11, pag	es 311-329;								
	Khoury,	J., et :	al., (1994) "Macro	phage	es adhere to	glud	cose-modified				
·	basement membrane via their scavenger receptors" J. Biol. Chem.,										
7	269:101	97-10200	•								
	Kindy, S. Mark and Rader, J. Daniel (1998) "Reduction in Amyloid A										
	Amyloid Formation in Apolipoprotein-E-Deficient Mice, " American										
ŀ	Journal of Pathology 152:1387-1395.										
	Marui, N., et al. (1993) "VCAM-1 gene transcription and expression ar										
	regulated through an oxidant-sensitive mechanism in human vascular										
ĺ	endothe	lial celi	ls" J. Clin. Inves	t., 9	92:1866-1874.	<del></del>					
	Nakamura, Y. et al. (1993) Immunohistochemical localization of										
EW	advanced glycosylation endproducts in coronary atheroma and cardiac										
	tissue	in diabet	tes mellitus. Am.	J. :	Pathol. 143(6	5):1	649-1656.				
	Nakashima Y, Plump A, Raines E, Breslow J, Ross R: ApoE-deficient mic										
	develop lesions of all phases of atherosclerosis throughout the										
	arteria	l tree.	Arterioscler Throm	b 19	94;141:133-14	10.					
_	Neeper,	M., et a	al. (1992). Cloni	ng a	nd expression	n of	a cell surfac				
EW	receptor for advanced glycosylation end products of proteins. J. Biol										
	Chem. 2	67: 14998	3-15004.								
EXAMINER	eluiri la	rav. Weslez	DATE CONSIDERED 6	14/0	/						
ine through		if not in cor	nsidered, whether or not consider								

Form P	TO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 0575/52876/JPW/JMI	Serial No. CPA2 of 08/905,709									
		ON DISCLOSURE STATEMENT	Applicant David Stern and An	ı-Marie Schmidt									
	(Use s	several sheets if necessary)	Filing Date March 23, 2000	Group 1646									
	OTHE	R DOCUMENTS (Including Author, Ti	tle, Date, Pertinent Pag	es, Etc.)									
	Palinsk	i, W. et al. (1995) Immunolog	ical evidence for	the presence of									
PW	advance	advanced glycation end products in atherosclerotic lesions of											
	euglycemic rabbits. Arterioscl. Thromb. And Vasc. Biol. 15(5):571-582												
	1	., et al. (1998) "Suppression	<del></del>										
	atherosclerosis by soluble Receptor for AGE (sRAGE)" Nature Medicine,												
	4:1025-1031.												
	Park, L	., et al. (1997). A murine	model of accelera	ited diabetic									
	atherosclerosis: suppression by soluble receptor for advanced												
	glycation endproducts. <u>Circulation Supplement</u> . Abstract 3079												
•	Ritthaler, et al. (1995) Expression of receptors for advanced												
	glycation end products in peripheral occulsive vascular disease. Am												
	J. Path. 146:688-694.												
	Schmidt	Schmidt, A. M. et al. (1993) Regulation of human mononuclear phagocyte											
ريري	migration	migration by cell surface-binding proteins for advanced glycation end											
Em.	products. J. Clin. Invest. 92:2155-2168.												
	Schmidt, A. M., et al. (1997) "The V-Domain of Receptor for Advanced												
	Glycation Endproducts (RAGE) mediates binding of AGEs: a novel targe												
	for therapy of diabetes" Circulation Supplement, 96:#194, p. I -37.												
	Schmidt, A-M, et al. (1994) "Cellular receptors for advanced glycation												
	end products" Arterioscler. Thromb., 14:1521-1528.												
	Schmidt, A. M., et al (1995) "The Dark Side of Glucose (News and												
	Views)"	Views)" Nature Medicine, 1:1002-1004.											
l l													
EXAMIN	ER Ve lazen - We	play DATE CONSIDERED 6/2	[0]										
*EXAMINE line thr	R: Initial if r	reference considered, whether or not cita f not in conformance and not considered.	tion is in conformance of Include copy of this f	with MPEP 609: Draw rom with next									

Form PTC	0-1449 U.S. Department of Comme Patent and Trademark Office		Atty. Docket No. 0575/52876/JPW/JM	Serial No. L CPA2 of 08/905,709							
IN	FORMATION DISCLOSURE STATEMENT										
	(Use several sheets if necessary)		Filing Date March 23, 2000	Group 1646							
	OTHER DOCUMENTS (Including Auth	or, Title	, Date, Pertinent Pag	ges, Etc.)							
1	Schmidt, A-M, et al. (1994) "Receptor for advanced glycation										
_ \	endproducts (AGEs) has a central	role	in vessel wall	interactions an							
EW	gene activation in response to circulating AGE proteins" Proc. Natl										
}	Acad. Sci. (USA), 91:8807-8811.										
	Schmidt A-M, Yan S-D, Wautier J	-L, St	ern DM: Activat	ion of RAGE: a							
	mechanism for chronic dysfunction										
	atherosclerosis. Circ Res 1999;84:489-497.										
	Vlassara, H., et al. (1995) "Ide	ntific	cation of Galec	tin- <b>Z</b> as a high							
	affinity binding protein for Advanced Glycation Endproducts (AGE):										
Em	new member of the AGE-Receptor co	omplex'	<u>Molecular Med</u>	<u>licine</u> , 1:634-646							
	Vlassara, H., et al. (1994). Pathogenic effects of advanced										
	glycosylation: biochemical, bio										
	diabetes and aging. <u>Lab. Invest</u>		<del></del>								
	Wautier, J. L., et al. (1996) "F	Recepto	or-mediated end	othelial							
	dysfunction in diabetic vasculo	pathy:	sRAGE blocks h	nyperpermeabilit							
	in diabetic rats" J. Clin. Inves	st., 9	7 (1):238-243.								
	Wautier, JL., et al. (1996).	Intera	ction of diabet	cic erythrocytes							
	bearing advanced glycation endproducts with the endothelial rece										
	AGE induces generation of react:	ates and cellula									
	dysfunction. Circulation Supplement 94(8): #4139. and										
	Yan, S-D., et al. (1994) "Enhance	ed ce	llular oxidant	stress by the							
	interaction of advanced glycation endproducts with their										
	receptors/binding proteins" J. Biol. Chem., 269:9889-9897.										
EXAMINER Liak	larar - Wesley DATE CONSIDERED	6/21/	10)								
ine throug	Initial if reference considered, whether or not the citation if not in conformance and not consider to applicant.										

\* ...